Astellas Pharma Inc. (ALPMF) on Decifer

Decifer ranks ALPMF number 72 of 277 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 13% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 13% a year and profits grew 480% over the past year.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Revenue growing about 13% with profits up 480% helps, but momentum of 13 out of 35 and no worldview role keep it in the middle.

The current read

The evidence on ALPMF lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Astellas Pharma Inc. operates in drug manufacturers - general. That places it inside the Healthcare, Biotech & Devices story.

Read the full ALPMF research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.